TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00528008

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: povidone-iodine solution
Description: Abdominal surgical field cleaned with 5% povidone-iodine detergent scrub, detergent cleaned from surgical area with sterile water, and then painted with 1% povidone-iodine solution.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: chlorhexidine gluconate
Description: Abdominal surgical field painted once using 2% chlorhexidine in 70% alcohol.
Study: NCT02708472

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: synchronized Transcranial Magnetic Stimulation (sTMS)
Description: Subjects who qualify will receive daily active sTMS treatments with the NeoSync, Inc sTMS device. The device includes an EEG recording module and the device uses a proprietary algorithm to determine the individualized alpha frequency (IAF). The IAF obtained during this baseline recording is used throughout the study.~The device contains three magnets in the sagittal line above the subject's scalp, which rotate along a transverse axis. sTMS stimulation is delivered broadly over the prefrontal and frontal regions of the brain. These magnets rotate to generate a sinusoidal magnetic field set at precisely the average individualized alpha frequency (IAF). Each therapy session lasts 30 minutes.
Study: NCT03507881

Intervention type: DEVICE
Intervention: fusion
Description: Internal fixation
Study: NCT02596802

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FETO therapy
Description: Fetoscopic surgery at 27 to 31 weeks and 6 days gestation.
Study: NCT01211119

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No PRF
Description: Group B (n=6), implantation of PRF after partial menisectomy and suture; Group (n=6), partial menisectomy only
Study: NCT01138397

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza virus vaccine (split virion, inactivated)
Description: 0.1 mL, Intradermal

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Influenza virus vaccine (split virion, inactivated)
Description: 0.1 mL, Intradermal
Study: NCT02680561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate MDPI
Study: NCT00963781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Reduced duration (6 months) DAPT
Study: NCT01489631

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naropin
Description: ropivacaine 0,2%, 3x 50 ml during surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: naropin
Description: ropivacaine 0,2%, 3x 50 ml during surgery

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: marcaine
Description: bupivacaine 0,125%

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sufentanil
Description: sufentanil 1mcg/ml

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: neurontin
Description: gabapentin 600 mg pre-operative 3 dd 300 mg
Study: NCT05830149

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cryoinsufflation
Description: In cryoinsufflation, local anesthesia will be administered to the tract area with lidocaine hydrochloride 1% or a similar local anesthetic. A needle will be mounted on a liquid nitrogen cryosurgical unit. The needle will be inserted through the entire sinus tract and cryospray will be delivered to the length of the sinus tract as the needle is retracted with the intention to induce local tissue destruction. Each spray will be 5 seconds in duration and each tract will be sprayed 3 times per treatment session. This technique has been shown to be effective in sinus tract obliteration. This intervention may prevent local disease progression and prevent patients from undergoing more invasive surgeries. Overall, this would result in improved cosmesis, decreased pain, decreased bleeding and improved patient satisfaction.
Study: NCT03153449

Intervention type: DEVICE
Group type: OTHER
Intervention: ATTUNE Revision Knee System in Total Knee Arthroplasty
Description: Implants from the ATTUNE Revision Knee System will be used to treat subjects whose surgeons have determined their anatomy is such that the use of revision components are required to perform primary total knee arthroplasty
Study: NCT02680561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate MDPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate MDPI
Study: NCT05830149

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deroofing
Description: Deroofing will serve as the control group as this is a minimally invasive procedure that is used for sinus tracts in HS. Studies have demonstrataed the efficacy of deroofing in treating the draining sinus tracts in HS. The control group should have decreased drainage, pain, recurrence, and scarring. In deroofing, local anesthesia will be administered to the tract area with lidocaine hydrochloride 1% or a similar local anesthetic. The sinus tract is probed to clearly defined the sinus tract. The skin overlying the sinus tract is cut using an a scalpel. In this way, the top of the sinus tract is surgically removed. In this way, the top of the sinus tract is surgically removed. The floor of the sinus tract is exposed and left open to heal by secondary intention.
Study: NCT01523990

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Available in two different unit doses, 1.1 mL and 4.1 mL PEG 400 in 5-mL type 1 glass syringes. They are identical in appearance and similar in weight to TG-2349 oral liquid syringes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Available in two different unit doses, 1.1 mL and 4.1 mL PEG 400 in 5-mL type 1 glass syringes. They are identical in appearance and similar in weight to TG-2349 oral liquid syringes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Available in two different unit doses, 1.1 mL and 4.1 mL PEG 400 in 5-mL type 1 glass syringes. They are identical in appearance and similar in weight to TG-2349 oral liquid syringes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Available in two different unit doses, 1.1 mL and 4.1 mL PEG 400 in 5-mL type 1 glass syringes. They are identical in appearance and similar in weight to TG-2349 oral liquid syringes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Available in two different unit doses, 1.1 mL and 4.1 mL PEG 400 in 5-mL type 1 glass syringes. They are identical in appearance and similar in weight to TG-2349 oral liquid syringes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Available in two different unit doses, 1.1 mL and 4.1 mL PEG 400 in 5-mL type 1 glass syringes. They are identical in appearance and similar in weight to TG-2349 oral liquid syringes.
Study: NCT00893737

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sumatriptan succinate 85 mg/naproxen sodium 500 mg (Treximet)
Description: Treximet 1 tablet as soon as the patient has headache indicative of migraine. May be repeated between 2 and 24 hours post-treatment for persistent or recurring headache. Subjects should not take more than 2 Treximet tablets in 24 hours.
Study: NCT01523990

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Available in two different unit doses, 1.1 mL and 4.1 mL PEG 400 in 5-mL type 1 glass syringes. They are identical in appearance and similar in weight to TG-2349 oral liquid syringes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Available in two different unit doses, 1.1 mL and 4.1 mL PEG 400 in 5-mL type 1 glass syringes. They are identical in appearance and similar in weight to TG-2349 oral liquid syringes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Available in two different unit doses, 1.1 mL and 4.1 mL PEG 400 in 5-mL type 1 glass syringes. They are identical in appearance and similar in weight to TG-2349 oral liquid syringes.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Available in two different unit doses, 1.1 mL and 4.1 mL PEG 400 in 5-mL type 1 glass syringes. They are identical in appearance and similar in weight to TG-2349 oral liquid syringes.
Study: NCT04010149

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: For the first two weeks of the study, participants will receive 20 min of brain stimulation, concurrent with cognitive training. Electrodes will be placed over the dorsolateral prefrontal cortex (active electrode), and the contralateral supraorbital site (return electrode).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: SHAM tDCS
Description: For the first two weeks of the study, participants will receive 20 min of SHAM brain stimulation, concurrent with cognitive training. Electrodes will be placed over the dorsolateral prefrontal cortex (active electrode), and the contralateral supraorbital site (return electrode).
Study: NCT01728064

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPI-743 400 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EPI-743 200 mg
Study: NCT01827605

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ZEVALIN
Description: Infusion of 90Y Ibritumomab Tiuxetan if the patient has less than 25% BM infiltration at the pre-consolidation restaging (0.4 mCi/kg if platelets ≥150,000/mmc, 0.3 mCi/kg if platelets are between 100.000 and 150,000/mmc).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BEAM
Description: BEAM REGIMEN day -6 Carmustine\* 300 mg/ m2 i.v. in 250ml dextrose 5% solution~from day -5 to day -2 Cytarabine 200 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr Etoposide 100 mg/m2 i.v. every 12 hours in 250 ml dextrose 5% solution, 250 ml/hr day -1 Melphalan 140 mg/m2 i.v. in 100ml saline solution in 200 ml/hr~day 0~UReinfusion of autologous stem cells following this rules:~1. Patient collecting ≥6x106 CD34+ cells/kg use \>4x106 CD34+ cells/kg for ASCT and keep \>2x106 CD34+ cells/kg for back up;~2. Patient collecting 4-6x106 CD34+ cells/kg use \>2x106 CD34+ cells/kg for ASCT and keep \>2x106 CD34+ cells/kg for back up;~3. Patient collecting 2-4x106 CD34+ cells/kg use all CD34+ cells for ASCT and keep no back up.~day 2 Filgrastim or Lenograstim 5μg/Kg s.c. until ANC \> 1500/mmc
Study: NCT02282579

Intervention type: DRUG
Intervention: Pazopanib
Description: Non interventional study
Study: NCT04546438

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: miraDry®
Description: MiraDry is a noninvasive method that uses microwave technology to destroy sweat glands.~In this study we evaluate a higher energy level with a newer generation device, in respect with side effects and number of treatments (one or two interventions).
Study: NCT02680561

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Salmeterol MDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone Propionate/Salmeterol MDPI

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone Propionate/Salmeterol MDPI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate/salmeterol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone propionate/salmeterol
Study: NCT01736709

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 2012-2013 trivalent seasonal influenza vaccine
Description: trivalent seasonal influenza vaccine with 0.25 ml ⁄ vial, for infants trivalent seasonal influenza vaccine with 0.5 ml ⁄ vial, for adults and old people
Study: NCT00255008

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2b
Description: Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2b
Description: Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: peginterferon alfa-2b
Description: Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin
Description: 200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg daily for up to 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin
Description: 200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg daily for up to 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ribavirin
Description: 200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg daily for up to 48 weeks

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2b
Description: Powder for injection in Redipen (50, 80, 100, 120, and 150 microgram strengths), subcutaneous, dose of 1.5 micrograms/kg, weekly for up to 24 weeks
Study: NCT04310969

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MiBoFlo Thermoflo
Description: Each treatment for each eye takes 10 minutes and is treated every two weeks for a total of three times. The device was preheated to 42.2℃ and the eyelid was cleaned and smeared with a small amount of ultrasound gel in order to reduce friction between the device and eyelid skin. Then massage the outer skin of the upper and lower eyelids for a period of 10 minutes. The patient's eyes keep closed during therapy.

Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: forceful expression of the meibomian glands
Description: Utilize a cotton swab on the inner surface of the eyelid and the another cotton swab on the outer lid to apply force

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: forceful expression of the meibomian glands
Description: Utilize a cotton swab on the inner surface of the eyelid and the another cotton swab on the outer lid to apply force

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: LipiFlow
Description: LipiFlow treatment applies heat to the palpebral surface of eyelids while simultaneously applying graded pulsatile pressure to the outer eyelid surfaces, thereby expressing the meibomian glands during heating.
Study: NCT03343652

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: 3 mg/kg IV infusion on day 1,14 up to 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bendamustine Hydrochloride
Description: 90 mg/kg IV infusion on day 1 up to 3 cycles
Study: NCT02734654

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: remote ischemic preconditioning (RIPC)
Description: Remote ischemic preconditioning: The limb RIPC was applied after the induction of anaesthesia and consisted of 3 cycles: 5 min of ischemia by a cuff-inflator on a thigh and inflated to 200 mmHg, followed by 5 min deflated. The control group had during the same time a deflated cuff on a thigh.
Study: NCT02337959

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Live subjects will receive two x-rays, one with predicate detector and one using the GOS or CsI investigational detector. Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detectors.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Live subjects will receive two x-rays, one with predicate detector and one using the GOS or CsI investigational detector. Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detectors.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation
Description: Live subjects will receive two x-rays, one with predicate detector and one using the GOS or CsI investigational detector. Multiple exams (head, chest, legs, etc) were made on the cadavers. Each exam area received one x-ray using the predicate detector and two x-rays using both the GoS and the CsI investigational detectors.
Study: NCT03058432

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy alone

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Concurrent chemoradiotherapy
Study: NCT04557020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 antibody
Description: neoadjuvant: PD-1 inhibitor Toripalimab 240mg combined with neoadjuvant chemotherapy by cis Platinum and gemcitabine every 3 weeks for 3 cycles ; adjuvant: Toripalimab 240mg every 3 weeks for 9 cycles after concurrent chemoradiotherapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: neoadjuvant chemotherapy: 1000mg/m2 in day 1 and day 8 and repeats every 3 weeks for 3 cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine
Description: neoadjuvant chemotherapy: 1000mg/m2 in day 1 and day 8 and repeats every 3 weeks for 3 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: neoadjuvant chemotherapy: 80mg/m2 in day 1, and repeats every 3 weeks for 3 cycles. Concurrent chemoradiotherapy: Cisplatin 100mg/m2 in day 1, 22, and 43 during IMRT
Study: NCT04248725

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: E-TIPS
Description: Chronic pain self-management strategies for employed individuals with physical disabilities
Study: NCT04453774

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Covidfree@home
Description: Mobile phone, Covidfree@home app, thermometer, pulse oximeter, smart watch
Study: NCT04094311

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTL019
Description: A single intravenous (i.v.) infusion of CAR-positive viable T cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTL019
Description: A single intravenous (i.v.) infusion of CAR-positive viable T cells.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CTL019
Description: A single intravenous (i.v.) infusion of CAR-positive viable T cells.
Study: NCT03392467

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PNEUMOSTEM
Description: human umbilical cord blood-derived mesenchymal stem cells

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline
Study: NCT04557020

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin
Description: neoadjuvant chemotherapy: 80mg/m2 in day 1, and repeats every 3 weeks for 3 cycles. Concurrent chemoradiotherapy: Cisplatin 100mg/m2 in day 1, 22, and 43 during IMRT

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: 70Gy to GTV, 60Gy to CTV1 and 54Gy to CTV2 in 32 to 33 fractions

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: IMRT
Description: 70Gy to GTV, 60Gy to CTV1 and 54Gy to CTV2 in 32 to 33 fractions
Study: NCT01568970

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Return-to-work Rehabilitation + Follow up
Description: 3 1/2 weeks of Return-to-work rehabilitation followed by 6 months of Return-to-work follow-up

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Return-to-work rehabilitation
Description: 3 1/2 weeks of Return-to-work rehabilitation followed by standard follow-up
Study: NCT01104467

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmoteplase
Description: 1 bolus injection of desmoteplase 70 µg/kg intravenous (IV)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmoteplase
Description: 1 bolus injection of desmoteplase 90 µg/kg (IV)
Study: NCT00255008

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ribavirin
Description: 200 mg capsules, oral, weight-based dose of 800, 1000, or 1200 mg daily for up to 24 weeks
Study: NCT01104467

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 1 bolus injection of placebo IV
Study: NCT01604135

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Corneal Collagen Crosslinking
Description: Keratoconic corneas that show significant progression as specified in the inclusion criteria section will receive one single treatment with CXL if randomized to the treatment arm. A treatment protocol based on 30 minutes dropping with riboflavin/dextran solution and 10 minutes UV-illumination treatment will be used.
Study: NCT03233711

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biopsy
Description: Undergo biopsy
Study: NCT00422240

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene/Benzoyl Peroxide
Description: Adapalene 0.1 % \[weight by weight (W/W)\]/benzoyl peroxide 2.5 % (W/W) gel topically daily in the evening for 12 Weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adapalene Gel, 0.1%
Description: 0.1% of adapalene gel topically daily in the evening for 12 Weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzoyl Peroxide Gel 2.5%
Description: 2.5% of benzoyl peroxide gel topically daily in the evening for 12 Weeks.
Study: NCT03233711

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Colonoscopy
Description: Undergo colonoscopy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Colonoscopy
Description: Undergo colonoscopy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Computed Tomography
Description: Undergo CT scan
Study: NCT02697864

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tafamidis
Study: NCT01445262

Intervention type: DRUG
Intervention: Levocetirizine
Study: NCT01523171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAR302503
Description: Pharmaceutical form:capsule~Route of administration: oral
Study: NCT02705469

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZEN003694